Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Blume-Jensen Peter. Director active across 1 company, notably Acrivon Therapeutics, Inc.. Aggregated, 23 filings have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €71k. History available since 14 November 2022. The latest transaction was filed on 21 May 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Blume-Jensen Peter
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Blume-Jensen Peter is a declarant linked to Acrivon Therapeutics, Inc. on XNAS, where the listed role is President and CEO. He has 23 filings in total, and within the sampled recent filings the purchases total 70538 EUR and the sales total 0 EUR, over a period from 2022-11-16 to 2026-05-26, with Retenue fiscale as the most frequent transaction nature.